Why These Researchers Are Concerned About Psychedelic Legalization

Why These Researchers Are Concerned About Psychedelic Legalization

Two researchers argue we still can’t be sure what the effects of widespread public use of psychedelics would be, and point to possible negatives.

Meet MindMed’s Interim CEO: Robert Barrow | My First Impressions & Comments

MindMed's Interim CEO, Robert Barrow, has not made as many public appearances as opposed to MMED's previous CEO, Jr Rahn. As many of you know, almost two months ago, then MindMed's CEO, JR Rahn, announced that he was stepping down, and he would be replaced immediately by Robert Barrow, then Chief Development Officer. Since then, we have not had a lot of news from the company, and though we have heard from Barrow on previous Conference Calls, us the retail investors, have not had a chance to meet the man (at least digitally) as CEO yet. That changed on August 3rd, when MNMD held a “fireside chat” over Zoom with Barrow, where we got to know him a little better, and he provided us with some new information. In this video, we will play the most important clips and offer some commentary where necessary. Enjoy the episode! Follow us on social media! 🙌 Instagram: @thepsychedelicinvestor Facebook: @thepsychedelicinvestor Want to collaborate? Send us an email at: thepsychedelicinvestor@gmail.com Music from: www.bensound.com Video editing: @themyaholy Check out our Benziga discounts https://benzinga.grsm.io/jameshallifax1834 https://benzinga.grsm.io/thepsychedelicinvestor DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments. All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change. #MindMed #MindMedStock #MNMD

The Spotlight Roundup- This Psychedelic VR Startup Raises Over $11 Million

August 4, 2021- This week’s Psychedelic Business News top stories include: - Virtual reality startup, Tripp Inc., raises $11 million - Research from Numinus involving psychedelics for PTSD makes significant strides - We catch up with…
FDA Green Lights Ketamine for Treatment of ALS

FDA Green Lights Ketamine for Treatment of ALS

,
"This designation not only expedites our regulatory, clinical, and product development plans but also validates our belief in the potential of ketamine," says PharmaTher CEO Fabio Chianelli.
Fireside Project Releases App for Psychedelic Peer Support

Fireside Project Releases App for Psychedelic Peer Support

"Our app was designed with accessibility and ease of use as top priorities, so that psychedelic users in any state of mind can connect quickly with our diverse and compassionate peer support line volunteers," says the nonprofit's co-founder.

Interview With Dimensions Health Centers

In today’s episode of the Psychedelic Spotlight podcast, we spotlight Dimensions Health Centers who are creating a new paradigm for hospitality by helping people to improve and transform their lives by drawing on the restorative power of nature, spa rituals, delicious food, and psilocybin-inspired ceremonies in safe, legal and luxurious settings.
Majority of Canadians Support Psilocybin-Assisted Therapy, According to New Poll

Majority of Canadians Support Psilocybin-Assisted Therapy, According to New Poll

As a result, the Canadian Psychedelic Association responds with a Memorandum of Regulatory Approval, which advises medicinal psilocybin therapy to be authorized in a safe and therapeutic environment.

Mindset Pharma Files Patent for Quickest, Cheapest Method to Synthesize Psilocybin

"Based on our research, we think we're able to get to psilocybin in fewer steps than any of the other published methods," says the company's CEO.
Australia’s First Psychedelic Research Institute Psychae Opens with $40 Million Investment

Australia’s First Psychedelic Research Institute Opens with $40 Million Investment

Psychae Institute will collaborate with other clinical research organizations to develop novel psychedelic medicines and accompanying psychotherapeutic treatment models.
Grand Rapids May Be Second City in Michigan to Decriminalize Natural Psychedelics by Year’s End

Grand Rapids May Be Second Michigan City to Decriminalize Natural Psychedelics by Year’s End

City Commissioner Kurt Reppart believes there is enough support to pass a resolution as early as fall.